EGFR and malignant glioma: Clinical findings reveal that only 10–20% of malignant glioma patients benefit from the gefitinib and the coexpression of the EGFRvIII oncogene, and the PTEN tumor suppressor protein in patients favors a clinical response to EGFR inhibitor therapy.